康希诺生物

Company News

Home >Newsroom >Company News

CanSinoBIO Launches First-in-Class Three-Component LNP Delivery System: Enhances T Cell Response and Safety, Surpassing Industry Patent Barriers

CanSinoBIO Obtained Approval for Clinical Trials on Inhaled TB Vaccine in Indonesia

SPIMACO and CanSinoBIO Sign an Agreement to Localise and Market the MCV4 Vaccine in Saudi Arabia and MENA

Professor Adrian V. S. Hill FRS from Oxford University Visits CanSinoBIO, Highlights Vaccine Innovations

CanSinoBIO Obtained Approval for Clinical Trials on DTcP-Hib-MCV4 Combined Vaccine

CanSinoBIO Announces Priority Review Status for DTcP Infant

CanSinoBIO Obtained Halal Decree of Menhycia® in Indonesia

CanSinoBIO Received Acceptance of New Drug Application for its Tetanus Vaccine

CanSinoBIO Secures Further Grant Funding

CanSinoBIO Executives Talk with WHO Experts on the Development Progress of Polio Vaccines

1 2 3 4 5 6 8